Financhill
Sell
47

AXGN Quote, Financials, Valuation and Earnings

Last price:
$12.57
Seasonality move :
12.1%
Day range:
$16.21 - $16.80
52-week range:
$5.65 - $21.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.87x
P/B ratio:
6.99x
Volume:
655.8K
Avg. volume:
469.4K
1-year change:
181.13%
Market cap:
$726.8M
Revenue:
$187.3M
EPS (TTM):
-$0.22

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
AXGN
Axogen
$48.3M $0.02 16.84% -76% $25.71
AHCO
AdaptHealth
$764.8M $0.04 35.77% 58.98% $12.67
ELMD
Electromed
$15.8M -- 13.91% -- $37.00
IRIX
IRIDEX
$12.8M -$0.12 -2.72% -18.18% --
MYO
Myomo
$9.2M -$0.08 145.61% -24% $9.25
STXS
Stereotaxis
$6.9M -$0.07 -0.07% -20.83% $4.50
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
AXGN
Axogen
$16.39 $25.71 $726.8M -- $0.00 0% 3.87x
AHCO
AdaptHealth
$8.24 $12.67 $1.1B 14.45x $0.00 0% 0.34x
ELMD
Electromed
$21.99 $37.00 $188.2M 29.32x $0.00 0% 3.30x
IRIX
IRIDEX
$1.15 -- $19.3M -- $0.00 0% 0.39x
MYO
Myomo
$4.84 $9.25 $166.4M -- $0.00 0% 5.61x
STXS
Stereotaxis
$2.09 $4.50 $179.7M -- $0.00 0% 6.61x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
AXGN
Axogen
31.37% 1.036 6.53% 1.88x
AHCO
AdaptHealth
55.53% 0.843 133.26% 0.82x
ELMD
Electromed
-- 2.545 -- 4.68x
IRIX
IRIDEX
51.25% 1.797 9.47% 0.73x
MYO
Myomo
-- 2.360 -- 2.82x
STXS
Stereotaxis
-- 1.450 -- 0.74x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
AXGN
Axogen
$37.6M $2M -6.89% -10.21% 4.56% $7.9M
AHCO
AdaptHealth
-$77M $23.2M 2.39% 5.59% 3.99% -$58K
ELMD
Electromed
$12.6M $2.5M 15.91% 15.91% 15.64% $2.9M
IRIX
IRIDEX
$4.3M -$1.9M -146.36% -157.91% -16.15% -$3.1M
MYO
Myomo
$8.6M -$245.3K -48.64% -48.64% -2.03% $2.5M
STXS
Stereotaxis
$3.2M -$7.6M -139.2% -139.2% -120.3% $1.3M

Axogen vs. Competitors

  • Which has Higher Returns AXGN or AHCO?

    AdaptHealth has a net margin of 0.91% compared to Axogen's net margin of -1.24%. Axogen's return on equity of -10.21% beat AdaptHealth's return on equity of 5.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    AXGN
    Axogen
    76.06% $0.01 $151.4M
    AHCO
    AdaptHealth
    -13.26% -$0.05 $3.5B
  • What do Analysts Say About AXGN or AHCO?

    Axogen has a consensus price target of $25.71, signalling upside risk potential of 56.89%. On the other hand AdaptHealth has an analysts' consensus of $12.67 which suggests that it could grow by 53.82%. Given that Axogen has higher upside potential than AdaptHealth, analysts believe Axogen is more attractive than AdaptHealth.

    Company Buy Ratings Hold Ratings Sell Ratings
    AXGN
    Axogen
    5 0 0
    AHCO
    AdaptHealth
    5 3 0
  • Is AXGN or AHCO More Risky?

    Axogen has a beta of 1.195, which suggesting that the stock is 19.457% more volatile than S&P 500. In comparison AdaptHealth has a beta of 1.639, suggesting its more volatile than the S&P 500 by 63.885%.

  • Which is a Better Dividend Stock AXGN or AHCO?

    Axogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AdaptHealth offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen pays -- of its earnings as a dividend. AdaptHealth pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AXGN or AHCO?

    Axogen quarterly revenues are $49.4M, which are smaller than AdaptHealth quarterly revenues of $580.5M. Axogen's net income of $450K is higher than AdaptHealth's net income of -$7.2M. Notably, Axogen's price-to-earnings ratio is -- while AdaptHealth's PE ratio is 14.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen is 3.87x versus 0.34x for AdaptHealth. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AXGN
    Axogen
    3.87x -- $49.4M $450K
    AHCO
    AdaptHealth
    0.34x 14.45x $580.5M -$7.2M
  • Which has Higher Returns AXGN or ELMD?

    Electromed has a net margin of 0.91% compared to Axogen's net margin of 12.11%. Axogen's return on equity of -10.21% beat Electromed's return on equity of 15.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    AXGN
    Axogen
    76.06% $0.01 $151.4M
    ELMD
    Electromed
    77.68% $0.22 $43.6M
  • What do Analysts Say About AXGN or ELMD?

    Axogen has a consensus price target of $25.71, signalling upside risk potential of 56.89%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 68.26%. Given that Electromed has higher upside potential than Axogen, analysts believe Electromed is more attractive than Axogen.

    Company Buy Ratings Hold Ratings Sell Ratings
    AXGN
    Axogen
    5 0 0
    ELMD
    Electromed
    2 0 0
  • Is AXGN or ELMD More Risky?

    Axogen has a beta of 1.195, which suggesting that the stock is 19.457% more volatile than S&P 500. In comparison Electromed has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.993%.

  • Which is a Better Dividend Stock AXGN or ELMD?

    Axogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AXGN or ELMD?

    Axogen quarterly revenues are $49.4M, which are larger than Electromed quarterly revenues of $16.3M. Axogen's net income of $450K is lower than Electromed's net income of $2M. Notably, Axogen's price-to-earnings ratio is -- while Electromed's PE ratio is 29.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen is 3.87x versus 3.30x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AXGN
    Axogen
    3.87x -- $49.4M $450K
    ELMD
    Electromed
    3.30x 29.32x $16.3M $2M
  • Which has Higher Returns AXGN or IRIX?

    IRIDEX has a net margin of 0.91% compared to Axogen's net margin of -16.69%. Axogen's return on equity of -10.21% beat IRIDEX's return on equity of -157.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    AXGN
    Axogen
    76.06% $0.01 $151.4M
    IRIX
    IRIDEX
    37.33% -$0.12 $5.4M
  • What do Analysts Say About AXGN or IRIX?

    Axogen has a consensus price target of $25.71, signalling upside risk potential of 56.89%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 73.91%. Given that IRIDEX has higher upside potential than Axogen, analysts believe IRIDEX is more attractive than Axogen.

    Company Buy Ratings Hold Ratings Sell Ratings
    AXGN
    Axogen
    5 0 0
    IRIX
    IRIDEX
    0 0 0
  • Is AXGN or IRIX More Risky?

    Axogen has a beta of 1.195, which suggesting that the stock is 19.457% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.819%.

  • Which is a Better Dividend Stock AXGN or IRIX?

    Axogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AXGN or IRIX?

    Axogen quarterly revenues are $49.4M, which are larger than IRIDEX quarterly revenues of $11.6M. Axogen's net income of $450K is higher than IRIDEX's net income of -$1.9M. Notably, Axogen's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen is 3.87x versus 0.39x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AXGN
    Axogen
    3.87x -- $49.4M $450K
    IRIX
    IRIDEX
    0.39x -- $11.6M -$1.9M
  • Which has Higher Returns AXGN or MYO?

    Myomo has a net margin of 0.91% compared to Axogen's net margin of -2.16%. Axogen's return on equity of -10.21% beat Myomo's return on equity of -48.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    AXGN
    Axogen
    76.06% $0.01 $151.4M
    MYO
    Myomo
    71.39% -$0.01 $24.7M
  • What do Analysts Say About AXGN or MYO?

    Axogen has a consensus price target of $25.71, signalling upside risk potential of 56.89%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 91.12%. Given that Myomo has higher upside potential than Axogen, analysts believe Myomo is more attractive than Axogen.

    Company Buy Ratings Hold Ratings Sell Ratings
    AXGN
    Axogen
    5 0 0
    MYO
    Myomo
    3 0 0
  • Is AXGN or MYO More Risky?

    Axogen has a beta of 1.195, which suggesting that the stock is 19.457% more volatile than S&P 500. In comparison Myomo has a beta of 1.633, suggesting its more volatile than the S&P 500 by 63.336%.

  • Which is a Better Dividend Stock AXGN or MYO?

    Axogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AXGN or MYO?

    Axogen quarterly revenues are $49.4M, which are larger than Myomo quarterly revenues of $12.1M. Axogen's net income of $450K is higher than Myomo's net income of -$260.1K. Notably, Axogen's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen is 3.87x versus 5.61x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AXGN
    Axogen
    3.87x -- $49.4M $450K
    MYO
    Myomo
    5.61x -- $12.1M -$260.1K
  • Which has Higher Returns AXGN or STXS?

    Stereotaxis has a net margin of 0.91% compared to Axogen's net margin of -118.53%. Axogen's return on equity of -10.21% beat Stereotaxis's return on equity of -139.2%.

    Company Gross Margin Earnings Per Share Invested Capital
    AXGN
    Axogen
    76.06% $0.01 $151.4M
    STXS
    Stereotaxis
    50.73% -$0.09 $11.4M
  • What do Analysts Say About AXGN or STXS?

    Axogen has a consensus price target of $25.71, signalling upside risk potential of 56.89%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 115.31%. Given that Stereotaxis has higher upside potential than Axogen, analysts believe Stereotaxis is more attractive than Axogen.

    Company Buy Ratings Hold Ratings Sell Ratings
    AXGN
    Axogen
    5 0 0
    STXS
    Stereotaxis
    2 0 0
  • Is AXGN or STXS More Risky?

    Axogen has a beta of 1.195, which suggesting that the stock is 19.457% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.088%.

  • Which is a Better Dividend Stock AXGN or STXS?

    Axogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AXGN or STXS?

    Axogen quarterly revenues are $49.4M, which are larger than Stereotaxis quarterly revenues of $6.3M. Axogen's net income of $450K is higher than Stereotaxis's net income of -$7.5M. Notably, Axogen's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen is 3.87x versus 6.61x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AXGN
    Axogen
    3.87x -- $49.4M $450K
    STXS
    Stereotaxis
    6.61x -- $6.3M -$7.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

5 Investors to Follow Other Than Warren Buffett
5 Investors to Follow Other Than Warren Buffett

There is no doubt that Warren Buffett is one of…

Is BYD a Threat To Tesla Shareholders?
Is BYD a Threat To Tesla Shareholders?

BYD (OTC:BYDDY) has rocketed to the top of China’s booming…

CVX Vs XOM Stock, Which Energy Play Is Best?
CVX Vs XOM Stock, Which Energy Play Is Best?

Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Buy
60
RGC alert for May 8

Regencell Bioscience Holdings [RGC] is up 10.54% over the past day.

Buy
92
TPB alert for May 8

Turning Point Brands [TPB] is down 6.67% over the past day.

Buy
74
LIVN alert for May 8

LivaNova PLC [LIVN] is up 1.33% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock